Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
Nicole Verdun(Center for Biologics Evaluation and Research), Peter Marks(Johns Hopkins University)
Cited by 257
Related Papers
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
|Journal of Clinical Investigation|2020|485
Safety Update
|Mayo Clinic Proceedings|2020|432
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
|Clinical Cancer Research|2015|165
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings
|Journal of Thrombosis and Haemostasis|2015|66